Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Van Meerbeeck

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesotheliomaL Y Dirix, J van Meerbeeck, D Schrijvers, et al.
The Journal of Pathology|March 1, 1994
Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA)M Ramael, W Jacobs, J Weyler, et al.
Oncology (Williston Park, N.Y.)|April 1, 1997
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of CancerG Giaccone, P E Postmus, T A Splinter, et al.
Plos Biology|November 24, 2020
Building resilience to mosquito-borne diseases in the CaribbeanRachel Lowe, Sadie J Ryan, Roché Mahon, et al.
Plos Medicine|July 18, 2018
Nonlinear and delayed impacts of climate on dengue risk in Barbados: A modelling studyRachel Lowe, Antonio Gasparrini, Cédric J Van Meerbeeck, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 1, 2012
Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?D De Ruysscher, J Van Meerbeeck, K Vandecasteele, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 1996
Second primary lung cancer in Flanders: frequency, clinical presentation, treatment and prognosisJ Van Meerbeeck, J Weyler, A Thibaut, et al.
British Journal of Cancer|September 1, 1996
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative GroupJ van Meerbeeck, C Debruyne, N van Zandwijk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2006
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975F Efficace, A Bottomley, E F Smit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative GroupP E Postmus, H Haaxma-Reiche, E F Smit, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesotheliomaL Y Dirix, J van Meerbeeck, D Schrijvers, et al.
The Journal of Pathology|March 1, 1994
Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA)M Ramael, W Jacobs, J Weyler, et al.
Oncology (Williston Park, N.Y.)|April 1, 1997
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of CancerG Giaccone, P E Postmus, T A Splinter, et al.
Plos Biology|November 24, 2020
Building resilience to mosquito-borne diseases in the CaribbeanRachel Lowe, Sadie J Ryan, Roché Mahon, et al.
Plos Medicine|July 18, 2018
Nonlinear and delayed impacts of climate on dengue risk in Barbados: A modelling studyRachel Lowe, Antonio Gasparrini, Cédric J Van Meerbeeck, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 1, 2012
Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?D De Ruysscher, J Van Meerbeeck, K Vandecasteele, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 1996
Second primary lung cancer in Flanders: frequency, clinical presentation, treatment and prognosisJ Van Meerbeeck, J Weyler, A Thibaut, et al.
British Journal of Cancer|September 1, 1996
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative GroupJ van Meerbeeck, C Debruyne, N van Zandwijk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2006
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975F Efficace, A Bottomley, E F Smit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative GroupP E Postmus, H Haaxma-Reiche, E F Smit, et al.
Pageof 5